GM-CSF-NEUTRALIZING ANTIBODIES FOR USE IN TREATING RHEUMATOID ARTHRITIS OR AS ANALGESICS Russian patent published in 2020 - IPC A61K39/395 A61P19/00 C07K16/24 

FIELD: medicine.

SUBSTANCE: invention relates to medicine and concerns use of a neutralizing antibody or its functional fragment specifically binding to primate GM-CSF, for treating an inflammatory disease selected from a group consisting of rheumatoid arthritis, SLE, psoriatic arthritis, ankylosing spondylitis, juvenile idiopathic arthritis and osteoarthritis. Neutralizing antibody or its functional fragment specifically binding to primate GM-CSF is administered to a patient in need thereof according to the following scheme: (I) first administration of a neutralizing antibody or functional fragment thereof, (II) subsequent second administration of a neutralizing antibody or functional fragment thereof for period of 7–21 days or period 21–35 days after the first administration, (III), followed by at least one addition of neutralizing antibody or its functional fragment for 21–35 days after said second administration, and (IV) subsequent one or more administrations of neutralizing antibody or its functional fragment with intervals of 21–35 days.

EFFECT: invention provides effective treatment of an inflammatory disease, such as rheumatoid arthritis, SLE, psoriatic arthritis, ankylosing spondylitis, juvenile idiopathic arthritis and osteoarthritis.

25 cl, 1 tbl, 2 ex